BBraun Indonesia (IFC-37527)

  • Indonesia
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Bank Risk Rating
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
Jan 18, 2016
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
The holder of the loan, grant, or other investment.
  • Construction
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 59.90 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD)
$ 55.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Jun 12, 2018

Disclosed by Bank Dec 17, 2015

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

The project finances the construction and operation of a Large Volume Parenteral healthcare product manufacturing plant in Indonesia.

Investment Description
  • International Finance Corporation (IFC)

The project consists of an A-loan to two Indonesian subsidiaries of B.Braun Melsungen AG, one of the world´s leading manufacturer and supplier of healthcare products. B.Braun Melsungen AG is a large private family-owned company created in 1839 by Julius Wilhelm Braun in Melsungen, Germany and which employs more than 54,000 people with an international presence in more than 60 countries. PT B.Braun Indonesia is fully owned by the Group while the second co-borrower, PT B.Braun Pharmaceutical Indonesia is owned at 85% by the Group and 15% by a local shareholder.

Contact Information

B.Braun Contact:
Mr Eko Peryatno
General Manager – Plant
Palma One Building, 14th Floor Suite 1401
Jl. HR Rasuna Said Kav, X-2 No. 4
Jakarta 12950, Indonesia
Tel: +62 21 5290 7177

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at You can learn more about the CAO and how to file a complaint at